The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories

Basit Öğe Kaydı
dc.authorid0000-0002-8909-2102en_US
dc.authorscopusid56035868800en_US
dc.authorwosidK-1194-2018en_US
dc.contributor.authorRazavi-Shearer, Devin
dc.contributor.authorChild, H.
dc.contributor.authorRazavi-Shearer, K.
dc.contributor.authorVoeller, A.
dc.contributor.authorRazavi, H.
dc.contributor.authorÖrmeci, Necati
dc.contributor.authorWu, J-C.
dc.contributor.authorYang, H-I.
dc.contributor.authorYu, M-L.
dc.contributor.authorYuen, M-F.
dc.contributor.authorYurdaydın, C.
dc.contributor.authorZuckerman, E.
dc.date.accessioned2023-12-07T14:15:47Z
dc.date.available2023-12-07T14:15:47Z
dc.date.issued2024en_US
dc.departmentFakülteler, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, İç Hastalıkları Ana Bilim Dalıen_US
dc.description.abstractBackground and aims: Hepatitis delta virus (HDV) is a satellite RNA virus that requires the hepatitis B virus (HBV) for assembly and propagation. Individuals infected with HDV progress to advanced liver disease faster than HBV mono-infected individuals. Recent studies have estimated the global prevalence of anti-HDV antibodies among the HBV-infected population to be 5-15%. This study aimed to better understand HDV prevalence at the population level in 25 countries/territories. Methods: We conducted a literature review for anti-HDV and HDV-RNA-positive prevalence in HBsAg positive individuals in 25 countries/territories. Virtual meetings were held with experts from each setting to discuss the findings and collect unpublished data. Data were weighted for patient segments and regional heterogeneity to estimate the prevalence in the HBV-infected population. The findings were then combined with The Polaris Observatory HBV data to estimate the anti-HDV & HDV-RNA prevalence in each country/territory at the population level. Results: After adjusting for geographical distribution, disease stage and special populations, the anti-HDV prevalence among the HBsAg+ population changed from the literature estimate in 19 countries. The highest anti-HDV prevalence was 60.1% in Mongolia. Once adjusted for the HBsAg+ population and HDV-RNA+, China had the highest absolute number of HDV-RNA+ cases. Conclusions: We found substantially lower HDV prevalence than previously reported, as prior meta-analyses primarily focused on studies conducted in groups/regions that have a higher probability of HBV infection: tertiary care centers, specific risk groups or geographical regions. There is large uncertainty in HDV prevalence. The implementation of reflex testing would improve estimates, while also allowing earlier linkage to care for HDV-RNA-positive individuals. The logistical and economic burden of reflex testing on the health system would be limited, as it would only screen HBsAg+ cases. Impact and implications: There is a great deal of uncertainty surrounding the prevalence of HDV among people living with HBV at the population level. This study aimed to better understand the burden in 25 countries and territories, to refine techniques that can be used in future analyses. We found a lower prevalence in the majority of places studied than had been previously reported. These data can help inform policy makers on the need to screen people living with HBV to find those coinfected with HDV and at high risk for progression, while also highlighting the pitfalls that other researchers have often fallen into.en_US
dc.identifier.citationRazavi-Shearer, D., Child, H., Razavi-Shearer, K., Voeller, A., Razavi, H., Örmeci, N., Wu, J-C., Yang, H-I., Yu, M-L., Yuen, M-F., Yurdaydın, C., & Zuckerman, E. (2024). The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories. Journal of Hepatology, 80(2), pp. 232-242. https://doi.org/10.1016/j.jhep.2023.10.043en_US
dc.identifier.doi10.1016/j.jhep.2023.10.043en_US
dc.identifier.endpage242en_US
dc.identifier.issn1600-0641
dc.identifier.issn0168-8278
dc.identifier.issue2en_US
dc.identifier.pmidPMID: 38030035en_US
dc.identifier.scopus2-s2.0-85181735099en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage232en_US
dc.identifier.urihttps://doi.org/10.1016/j.jhep.2023.10.043
dc.identifier.urihttps://hdl.handle.net/20.500.13055/594
dc.identifier.volume80en_US
dc.identifier.wosWOS:001184424500001en_US
dc.identifier.wosqualityQ1en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.indekslendigikaynak.otherSCI-E - Science Citation Index Expandeden_US
dc.institutionauthorÖrmeci, Necati
dc.language.isoenen_US
dc.publisherElsevieren_US
dc.relation.ispartofJournal of Hepatologyen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectEpidemiologyen_US
dc.subjectHepatitis Ben_US
dc.subjectHepatitis Den_US
dc.subjectHepatitis Delta Virusen_US
dc.subjectPrevalenceen_US
dc.subjectViral Hepatitisen_US
dc.titleThe adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territoriesen_US
dc.typeArticleen_US
dspace.entity.typePublication

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
The adjusted prevalence of hepatitis delta virus (HDV) in 25 countries and territories.pdf
Boyut:
788.58 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Kapalı Erişim
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

Dahili Tıp Bilimleri Bölümü Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu